These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20011245)

  • 1. The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab.
    Kelly R; Richards S; Hillmen P; Hill A
    Ther Clin Risk Manag; 2009; 5():911-21. PubMed ID: 20011245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
    Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
    Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
    Röth A; Dührsen U
    Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
    Nishimura JI
    Rinsho Ketsueki; 2018; 59(8):1042-1047. PubMed ID: 30185704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
    Szer J; Hill A; Weitz IC
    Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Rare Case of Paroxysmal Nocturnal Hemoglobinuria With Bilateral Renal Vein Thrombosis.
    Lodhi OUH; Sohail S; Hassan D
    Cureus; 2020 Jun; 12(6):e8806. PubMed ID: 32724752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria.
    Göker H; Uz B; Büyükaşık Y; Aksu S; Haznedaroğlu İ; Sayınalp N; Karacan Y; Tekin F; Özcebe Oİ
    Turk J Haematol; 2011 Sep; 28(3):223-7. PubMed ID: 27264371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria requiring transfusions 14 years after a diagnosis in childhood.
    Ueda T; Hayakawa J; Yamanishi M; Maeda M; Fukunaga Y
    J Nippon Med Sch; 2013; 80(2):155-9. PubMed ID: 23657069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.
    Zareba KM
    Drugs Today (Barc); 2007 Aug; 43(8):539-46. PubMed ID: 17925885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of a patient with classical paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome, with complement inhibitor eculizumab: Case Report.
    Mandala E; Lafaras C; Goulis I; Tsioni K; Georgopoulou V; Ilonidis G
    Hippokratia; 2013 Jan; 17(1):81-4. PubMed ID: 23935352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
    Stern RM; Connell NT
    Ther Adv Hematol; 2019; 10():2040620719874728. PubMed ID: 31534662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antibody therapy for paroxysmal nocturnal hemoglobinuria].
    Nishimura JI
    Rinsho Ketsueki; 2020; 61(8):929-936. PubMed ID: 32908057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
    Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
    Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab.
    Cooper JP; Farah RJ; Stevenson PA; Gooley TA; Storb R; Scott BL
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1331-1339. PubMed ID: 30711779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
    Notaro R; Sica M
    Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.